Market Cap 1.74B
Revenue (ttm) 36.56M
Net Income (ttm) -88.98M
EPS (ttm) N/A
PE Ratio 38.26
Forward PE 115.55
Profit Margin -243.38%
Debt to Equity Ratio 0.00
Volume 640,900
Avg Vol 1,206,636
Day's Range N/A - N/A
Shares Out 54.80M
Stochastic %K 29%
Beta 1.24
Analysts Strong Sell
Price Target $28.22

Company Profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevun...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 430 8200
Address:
45 Wiggins Avenue, Bedford, United States
BusinessStock
BusinessStock Oct. 23 at 6:31 PM
$STOK Go green
0 · Reply
TylerDurd3n
TylerDurd3n Oct. 16 at 7:22 PM
0 · Reply
LadsAndGents
LadsAndGents Oct. 16 at 1:59 PM
$STOK looks like this has even gone beyond the selling price ?
0 · Reply
Digger75
Digger75 Oct. 15 at 7:08 PM
0 · Reply
Digger75
Digger75 Oct. 15 at 6:09 PM
0 · Reply
TylerDurd3n
TylerDurd3n Oct. 15 at 8:10 AM
0 · Reply
TylerDurd3n
TylerDurd3n Oct. 14 at 5:39 PM
$STOK The best Stock hiding in plain sight! Love this thing!
2 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 9:55 AM
BTIG has updated their rating for Stoke Therapeutics ( $STOK ) to Buy with a price target of 39.
0 · Reply
LadsAndGents
LadsAndGents Oct. 10 at 7:07 PM
$STOK unreal given the day especially
0 · Reply
iatsebob
iatsebob Oct. 10 at 1:53 PM
$STOK good news on trial, analyst price upgrade, stock down?? What am I missing?
0 · Reply
Latest News on STOK
Stoke Therapeutics: Impressive Pipeline And Big Backers

Jun 15, 2025, 11:27 PM EDT - 4 months ago

Stoke Therapeutics: Impressive Pipeline And Big Backers


Stoke Therapeutics Stock Slips as CEO Steps Down

Mar 18, 2025, 12:56 PM EDT - 7 months ago

Stoke Therapeutics Stock Slips as CEO Steps Down


Stoke Therapeutics Announces CEO Transition

Mar 18, 2025, 6:58 AM EDT - 7 months ago

Stoke Therapeutics Announces CEO Transition


Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Feb 16, 2025, 2:23 PM EST - 8 months ago

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer


Stoke Therapeutics Announces Proposed Public Offering

Mar 26, 2024, 4:07 PM EDT - 1 year ago

Stoke Therapeutics Announces Proposed Public Offering


BusinessStock
BusinessStock Oct. 23 at 6:31 PM
$STOK Go green
0 · Reply
TylerDurd3n
TylerDurd3n Oct. 16 at 7:22 PM
0 · Reply
LadsAndGents
LadsAndGents Oct. 16 at 1:59 PM
$STOK looks like this has even gone beyond the selling price ?
0 · Reply
Digger75
Digger75 Oct. 15 at 7:08 PM
0 · Reply
Digger75
Digger75 Oct. 15 at 6:09 PM
0 · Reply
TylerDurd3n
TylerDurd3n Oct. 15 at 8:10 AM
0 · Reply
TylerDurd3n
TylerDurd3n Oct. 14 at 5:39 PM
$STOK The best Stock hiding in plain sight! Love this thing!
2 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 9:55 AM
BTIG has updated their rating for Stoke Therapeutics ( $STOK ) to Buy with a price target of 39.
0 · Reply
LadsAndGents
LadsAndGents Oct. 10 at 7:07 PM
$STOK unreal given the day especially
0 · Reply
iatsebob
iatsebob Oct. 10 at 1:53 PM
$STOK good news on trial, analyst price upgrade, stock down?? What am I missing?
0 · Reply
Quantumup
Quantumup Oct. 10 at 11:47 AM
Needham⬆️the PT on $STOK to $35 from $22 and reiterated at a Buy rating after STOK presented new zorevuneren OLE data in Dravet Syndrome (DS) at the 54th Child Neurology Society (CNS) annual meeting yesterday. [ $BIIB ] $JAZZ $UCBJY $UCBJF Needham said in its note: The new data showed 1) patients treated with zorevunersen had continued improvements in clinical outcomes through 3 years, and 2) an analysis of patients in the OLE who received a similar dosing regimen as the ongoing Ph3 trial continued to show improvements in the Vineland-3 (cognition & behavior) at 2 years vs. a DS natural history study. This new data, along with the positive 3-year OLE data shared in early August (see our note here), has increased our confidence in the long-term efficacy & durability of zorevunersen and the potential for significant differentiation (disease modification) over SoC anti-seizure drugs for the treatment of DS. We are raising our PT to $35 (was $22).
0 · Reply
JarvisFlow
JarvisFlow Oct. 10 at 10:22 AM
Needham updates rating for Stoke Therapeutics ( $STOK ) to Buy, target set at 22 → 35.
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:24 PM
Keep a close watch on CMCT! $STOK $TMRC $HOOD $GME
0 · Reply
iatsebob
iatsebob Oct. 9 at 10:55 PM
$STOK BOOM!! https://www.stocktitan.net/news/BIIB/biogen-and-stoke-therapeutics-present-new-data-at-the-54th-child-k6lvezke8d0i.html
0 · Reply
iatsebob
iatsebob Oct. 9 at 4:37 PM
$STOK float is locked up by the tutes.
0 · Reply
iatsebob
iatsebob Oct. 9 at 4:17 PM
0 · Reply
iatsebob
iatsebob Oct. 9 at 3:54 PM
$STOK WOW!
0 · Reply
iatsebob
iatsebob Oct. 9 at 3:20 PM
$STOK seems to me that it’s only a matter of time for $BIIB to buy this company. They are located about 30 minutes from Cambridge, MA. Coincidence?? I doubt it.
0 · Reply
iatsebob
iatsebob Oct. 9 at 1:43 AM
$STOK https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=STOK
0 · Reply
iatsebob
iatsebob Oct. 9 at 12:52 AM
$STOK https://www.timothysykes.com/news/stoke-therapeutics-inc.stok-news-2025_10_08/
0 · Reply
iatsebob
iatsebob Oct. 8 at 10:21 PM
$STOK I wonder if the new CEO still has good relationships with his old colleagues at $VRTX and could work with them to market this thing in North America?
0 · Reply
Doozio
Doozio Oct. 8 at 7:42 PM
👁️ $SPY be lucky to own $STOK s. Don’t be a 🐑 during 🐒🍌🧠⏰♾️ because it’s coming. It’s all coming.
0 · Reply